Skip to content
Screener

uniQure QURE Business Segments — Royalty Financing Agreement Interest Expense

Similar metrics at other companies

Iovance Biotherapeutics, Inc. logo
IOVASingle Reportable — Royalty Expense
$2.25M+83.1%
Natural Grocers by Vitamin Cottage logo
NGVCSingle Reportable — Interest Expense
$663K-4.5%
PVL
PVLAInterest Income Expense Nonoperating Royalty Agreement
-$2.04M-67.8%
PVL
PVLANoncash Interest Expense Income Royalty Agreement
$2.04M+67.8%
Capricor Therapeutics logo
CAPRSingle Reportable — Interest Expense Nonoperating
$761.43K
Ur-Energy logo
URGSingle Reportable — Interest Expense Nonoperating
$2.95M+1,008%

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Cash & equivalents$413.0M+62.8%
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept qure:RoyaltyFinancingAgreementInterestExpense.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Fair value (loss) / gain - contingent consideration(1,256)(2,254)82(3,470)
Fair value loss - Liability related to pre-funded warrants(15,970)(12,201)
Foreign currency (losses) / gains, net(1,730)18,638(4,024)25,810
Interest income5,0513,52410,2807,651
Interest expense - Royalty Financing Agreement(12,963)(13,770)(25,584)(27,079)
Interest expense - Hercules loan facility(1,403)(1,821)(2,813)(3,621)
Other reconciling items(5,387)(571)(5,188)4,561
Consolidated loss before income tax expense$(79,218)$(37,294)$(132,265)$(80,435)

Item 1.Financial Statements

FAQ

What is uniQure's business segments — royalty financing agreement interest expense?
uniQure (QURE) reported business segments — royalty financing agreement interest expense of $12.96M in Q2 2026.
How has uniQure's business segments — royalty financing agreement interest expense changed year-over-year?
uniQure's business segments — royalty financing agreement interest expense decreased by 5.9% year-over-year, from $13.77M to $12.96M.
What is the long-term trend for uniQure's business segments — royalty financing agreement interest expense?
Over 2 years (2023 to 2025), uniQure's business segments — royalty financing agreement interest expense has grown at a 41.7% compound annual growth rate (CAGR), from $26.93M to $54.1M.
What does business segments — royalty financing agreement interest expense mean?
Represents the cost of capital associated with financing arrangements where future royalty streams are pledged as collateral. This expense reflects the non-dilutive financing costs incurred to fund research and development activities. It is a vital metric for evaluating the company's long-term debt structure and future revenue commitments.

Ask your AI about uniQure's business segments — royalty financing agreement interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude